BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24549225)

  • 61. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study.
    Zimmermann M; Nickl S; Lambers C; Hacker S; Mitterbauer A; Hoetzenecker K; Rozsas A; Ostoros G; Laszlo V; Hofbauer H; Renyi-Vamos F; Klepetko W; Dome B; Ankersmit HJ
    Clin Chim Acta; 2012 Jul; 413(13-14):1115-20. PubMed ID: 22465083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer.
    Peng H; Wang J; Li J; Zhao M; Huang SK; Gu YY; Li Y; Sun XJ; Yang L; Luo Q; Huang CZ
    Life Sci; 2016 Apr; 151():235-242. PubMed ID: 26946307
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
    Ramírez de Molina A; Sarmentero-Estrada J; Belda-Iniesta C; Tarón M; Ramírez de Molina V; Cejas P; Skrzypski M; Gallego-Ortega D; de Castro J; Casado E; García-Cabezas MA; Sánchez JJ; Nistal M; Rosell R; González-Barón M; Lacal JC
    Lancet Oncol; 2007 Oct; 8(10):889-97. PubMed ID: 17851129
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism.
    Zhang PP; Sun JW; Wang XY; Liu XM; Li K
    Eur J Surg Oncol; 2013 Sep; 39(9):951-6. PubMed ID: 23810331
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma.
    Bartling B; Vanhooren V; Dewaele S; Libert C; Hofmann HS; Haerting J; Nuding S; Silber RE; Simm A; Chen CC
    Cancer Biomark; 2011-2012; 10(3-4):145-54. PubMed ID: 22674300
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
    Fan W; Yang H; Xue H; Sun Y; Zhang J
    Int J Clin Exp Pathol; 2015; 8(5):5503-8. PubMed ID: 26191257
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.
    Infante M; Allavena P; Garlanda C; Nebuloni M; Morenghi E; Rahal D; Roncalli M; Cavuto S; Pesce S; Monari M; Valaperta S; Montanelli A; Solomon D; Bottoni E; Errico V; Voulaz E; Bossi M; Chiesa G; Passera E; Mantovani A; Alloisio M
    Int J Cancer; 2016 Feb; 138(4):983-91. PubMed ID: 26348770
    [TBL] [Abstract][Full Text] [Related]  

  • 71. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
    Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
    Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients.
    Tomasetti M; Staffolani S; Nocchi L; Neuzil J; Strafella E; Manzella N; Mariotti L; Bracci M; Valentino M; Amati M; Santarelli L
    Clin Biochem; 2012 May; 45(7-8):575-81. PubMed ID: 22374169
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
    Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
    Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma.
    Iwamoto H; Kanda Y; Sejima T; Osaki M; Okada F; Takenaka A
    Int J Oncol; 2014 Jan; 44(1):53-8. PubMed ID: 24212760
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.
    Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
    Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
    Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL
    Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of serum proteome components associated with progression of non-small cell lung cancer.
    Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
    Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
    Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.